Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a research report released on Wednesday, MarketBeat reports. The firm issued an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. Weiss Ratings started coverage on Satellos Bioscience in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

Satellos Bioscience Price Performance

Shares of Satellos Bioscience stock opened at $10.00 on Wednesday. The stock has a market capitalization of $154.59 million, a price-to-earnings ratio of -8.33 and a beta of 1.10. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.